EU approves Roche's Avastin for platinum-resistant recurrent ovarian cancer

Roche announced today that the European Commission (EU) approved the use of Avastin (bevacizumab) in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin chemotherapy as a treatment for women with recurrent ovarian cancer that is resistant to platinum-containing chemotherapy.
Source: Roche Media News - Category: Pharmaceuticals Source Type: news